while in the fast evolving area of oncology investigation, precise and effective mutation screening is critical for producing qualified therapies. The KRAS companies Platform performs a pivotal role During this landscape by supplying detailed answers for KRAS mutation profiling and analysis. KRAS mutations, present in about 95% of RAS-connected onc